There is some debate as to whether GLP-1 agonist drugs like Wegovy can lead to unhealthy muscle mass loss in addition to ...

DehydraTECH-processed tirzepatide from Zepbound® is being tested in an oral dose format KELOWNA, BC / ACCESSWIRE / November ...

In the US, liraglutide, semaglutide, and tirzepatide are currently under investigation for their ability to stimulate weight ...

It’s unclear what impact a change in presidential administration will have on the proposal to widen access for those with obesity.

CHICAGO -- A long-acting GIP/GLP-1 receptor agonist conferred significant clinical benefit for people with obesity and ...

As well, Novo Nordisk® has earlier announced a successful outcome of a human trial of 3,533 people with CKD and type 2 diabetes using injected semaglutide. The study 'demonstrated a statistically ...

--(BUSINESS WIRE)--Olfactive Biosolutions, the leader in harnessing food molecules for the treatment of chronic diseases, has begun production of its Protenx™ GLP-1/GIP Weight Loss patented ...

MOUNTAIN VIEW, Calif., November 14, 2024--(BUSINESS WIRE)--Olfactive Biosolutions, the leader in harnessing food molecules ...

Recent studies have shown that pharmacological treatment with GLP-1-RA and dual GLP-1/glucose-dependent insulinotropic polypeptide receptor agonists (GIP-RA) causes almost as much weight loss as ...

The affected drugs are semaglutide (Ozempic, Rybelsus, Wegovy); liraglutide (Saxenda, Victoza); and the dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 tirzepatide (Mounjaro, ...